Decisions about which medical devices and drugs to use are crucial to the quality and sustainability of health care in Canada. Access to evidence-based information is key to making informed decisions that harness the benefits of technology while getting the best value from every health dollar.
The Institut national d’excellence en santé et en services sociaux was created on January 19, 2011. It succeeded the Conseil du médicament and the Agence d’évaluation des technologies et des modes d’intervention en santé (AETMIS). INESSS’s mission is to promote clinical excellence and the efficient use of resources in the health and social services sector. At the heart of the mission, INESSS assesses, in particular, the clinical advantages and the costs of the technologies, medications and interventions used in health care and personal social services. It issues recommendations concerning their adoption, use and coverage by the public plan, and develops guides to clinical practice in order to ensure their optimal use.
Haute Autorité de Santé (HAS) is an independent public scientific authority with financial autonomy. Its key purpose is to improve the quality of patient care and to guarantee equity within the healthcare system. It does this through the:
- assessment of drugs and medical devices
- certification of healthcare organisations and accreditations of doctors
- publication of guidelines (good practices, public health)
The Federal Joint Committee (G-BA) is the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany. It issues directives for the benefit catalogue of the statutory health insurance funds (GKV) for more than 70 million insured persons and thus specifies which services in medical care are reimbursed by the GKV. In addition, the G-BA specifies measures for quality assurance in inpatient and outpatient areas of the health care system.
The Health Information and Quality Authority (HIQA) is an independent authority established to drive high-quality and safe care for people using the health and social care services in Ireland. HIQA performs health technology assessments (HTAs) to evaluate the clinical and cost-effectiveness of health technologies and provides advice arising out of the evaluation to the Minister for Health and the Health Service Executive (HSE).
The National Centre for Pharmacoeconomics conducts the health technology assessment (HTA) of pharmaceutical products for the Health Service Executive (HSE) in Ireland in collaboration with the HSE Corporate Pharmaceutical Unit (HSE-CPU). The aim of the centre is to promote expertise in Ireland for the advancement of the discipline of pharmacoeconomics through practice, research and education.
The Italian Medicines Agency (AIFA, Agenzia Italiana del Farmaco), is the national authority responsible for regulating drugs in Italy.
Quality, accessibility and affordability are the pillars of the Dutch healthcare system. The Netherlands Healthcare Institute (Zorginstituut Nederland) ensures that these pillars form a strong foundation.They represent the interests of everyone who is entitled to care under the Health Insurance Act (Zvw) and the Long-Term Care Act (Wlz).
Ministry of Health, Consumption and Social Welfare.
The Dental and Pharmaceutical Benefits Agency, TLV, is a central government agency whose remit is to determine whether a pharmaceutical product or dental care procedure shall be subsidised by the state. We also contribute to quality service and accessibility of pharmacies.
The AWMSG is the Welsh health technology appraisal (HTA) body, a statutory advisory Welsh Assembly-sponsored public body which aims to provide advice on medicines management and prescribing to the Welsh Government’s Minister for Health and Social Services in an effective, efficient and transparent manner.
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. Reimbursement and uptake of medicines in England and Wales are based on the implementation of Health Technology Assessment (HTA) guidance produced by NICE.
SIGN provides evidence-based guidance on the diagnosis and management of specific conditions for the NHS in Scotland.
The remit of the Scottish Medicines Consortium (SMC) is to provide advice to NHS Boards and their Area Drug and Therapeutics Committees (ADTCs) across Scotland about the clinical and cost-effectiveness of all newly licensed medicines, all new formulations of existing medicines and new indications for established products (licensed from January 2002).